Evidence map›Paper›PMID 32397876›Full record

ArticleThe Journal of neuropsychiatry and clinical neurosciences2020

Effect of Functional BDNF and COMT Polymorphisms on Symptoms and Regional Brain Volume in Frontotemporal Dementia and Corticobasal Syndrome.

Edward D Huey, Rachel Fremont, Masood Manoochehri, Yunglin Gazes, Seonjoo Lee, Stephanie Cosentino, Michael Tierney, Eric M Wassermann, Parastoo Momeni, Jordan Grafman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of neuropsychiatry and clinical neurosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Central nervous system effects of 5-HTMolecular medicine (Cambridge, Mass.) · 2022
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Edward D HueyTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Rachel FremontTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Masood ManoochehriTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Yunglin GazesTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Seonjoo LeeTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Stephanie CosentinoTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Michael TierneyTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Eric M WassermannTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Parastoo MomeniTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Jordan GrafmanTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Columbia University · US

Funding

Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
Electrophysiological Probes And Treatments In Neurobehavioral DisordersZIANS002977 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI WASSERMANN, ERIC M · 2009 to 2025
$14.6M
PRIMING THE PUMP: TRAINING PHYSICIAN-SCIENTISTS IN TRANSLATIONAL PSYCHIATRYR25MH086466 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Melissa Arbuckle, Eduardo David Leonardo · 2009 to 2026
$4.3M
Genetic basis of neuropsychiatric symptoms in Alzheimer's diseaseU01AG079850 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gary Wayne Beecham, Edward D Huey · 2023 to 2026
$3.0M
Neuroanatomical associations with the factor structure underlying neuropsychiatric symptoms in Alzheimer's diseaseR01AG062268 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUEY, EDWARD D · 2018 to 2022
$2.5M
Using RDoC Negative and Positive Valence Paradigms to Investigate the Mechanisms of Neuropsychiatric Symptoms (NPS) in Alzheimer's Disease and Related DementiasR01MH120794 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HUEY, EDWARD D · 2019 to 2023
$2.1M
Investigation of the dopamine system in frontotemporal dementiaR00NS060766 · NINDS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI HUEY, EDWARD D · 2009 to 2011
$732k
NIA NIH HHS P50 AG008702NIA NIH HHS R01 AG062268NIA NIH HHS U01 AG079850NIMH NIH HHS R01 MH120794NIMH NIH HHS R25 MH086466NINDS NIH HHS R00 NS060766
6 · The paper itself

Abstract

objectiveThe authors examined the effects of two common functional polymorphisms-brain-derived neurotrophic factor (BDNF) Val66Met and catechol-

methodsThe BDNF Val66Met and COMT Val158Met polymorphisms were genotyped in 174 participants with FTLD syndromes, including behavioral variant frontotemporal dementia, primary progressive aphasia, and corticobasal syndrome. Gray matter volumes and scores on the Delis-Kaplan Executive Function System, Mattis Dementia Rating Scale, Wechsler Memory Scale, and Neuropsychiatric Inventory were compared between allele groups.

resultsThe BDNF Met allele at position 66 was associated with a decrease in depressive symptoms (F=9.50, df=1, 136, p=0.002). The COMT Val allele at position 158 was associated with impairment of executive function (F=6.14, df=1, 76, p=0.015) and decreased bilateral volume of the head of the caudate in patients with FTLD (uncorrected voxel-level threshold of p<0.001). Neither polymorphism had a significant effect on motor function.

conclusionsThese findings suggest that common functional polymorphisms likely contribute to the phenotypic variability seen in patients with FTLD syndromes. This is the first study to implicate

Indexed as

Basal Ganglia DiseasesDepressionFrontotemporal Lobar DegenerationAgedBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseExecutive FunctionFemaleGray MatterHumansMaleMiddle AgedPhenotypePolymorphism, Single NucleotideBDNF protein, humanBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCOMT protein, humanBDNFCOMTCorticobasal SyndromeDementiaFrontotemporal DementiaGenetics

Identifiers

PMID32397876
PMCPMC7606216
OpenAlexW3025921341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.